Most health insurance plans do not cover shockwave therapy for plantar fasciitis. The majority of major insurers classify the treatment as experimental, investigational, or unproven, which means claims are routinely denied. While the FDA has approved specific shockwave devices for plantar fasciitis and clinical guidelines support its use before surgery, that hasn’t translated into widespread insurance coverage.
What Major Insurers Say
UnitedHealthcare’s medical policy states that extracorporeal shockwave therapy (ESWT), “whether low energy, high energy, or radial wave, is unproven and not medically necessary for any musculoskeletal or soft tissue indications.” That blanket denial covers plantar fasciitis along with every other condition the therapy is used for.
Aetna takes a similar position. Its clinical policy bulletin lists plantar fasciitis under a long catalog of conditions for which it considers shockwave therapy “experimental, investigational, or unproven.” Aetna does cover ESWT for one specific condition, calcific tendinopathy of the shoulder, but that exception does not extend to heel pain. Blue Cross Blue Shield plans vary by region, but most follow the same pattern of classifying ESWT as investigational for plantar fasciitis.
Medicare coverage depends on your regional carrier. CMS has a local coverage determination (LCD L38775) that governs ESWT, but there is no national coverage determination requiring Medicare to pay for it. In practice, most Medicare beneficiaries will not find this treatment covered.
Why Insurers Deny Coverage Despite FDA Approval
This is the part that frustrates many patients. The FDA granted premarket approval to the OrthoSpec Extracorporeal Shock Wave Therapy Device specifically for treating plantar fasciitis in adults who have had symptoms for six months or longer and have not responded to conservative treatments. So the device is FDA-approved for exactly this use.
Insurance companies, however, set their own standard for “medically necessary,” and FDA clearance alone doesn’t guarantee coverage. Insurers review the clinical evidence independently and have concluded that the research, while promising, doesn’t yet meet their threshold. Their medical policy reviewers point to the diversity of treatment protocols across studies, differences in shockwave devices, and the fact that some trials show benefits fading by 24 weeks. Until insurers see what they consider consistent, high-quality evidence, the “experimental” label stays in place.
What Clinical Guidelines Actually Recommend
The insurance industry’s position is increasingly at odds with clinical practice guidelines. The 2023 Heel Pain/Plantar Fasciitis clinical practice guideline describes ESWT as a noninvasive option with meta-analytic support for medium- to long-term pain reduction. It recommends that shockwave therapy be considered before surgical treatment in patients with chronic plantar fasciitis who haven’t responded to other conservative care.
The International Society for Medical Shockwave Treatment (ISMST) has published specific treatment parameters for plantar fasciitis, recommending radial shockwave therapy at 2 to 4 bar pressure, up to 10 Hz frequency, and 2,000 to 3,000 pulses per session. Research comparing focused shockwave therapy to corticosteroid injections found that shockwave demonstrated superior long-term pain relief. These findings support ESWT as more than experimental, but insurers have been slow to update their policies.
Focused vs. Radial Shockwave Therapy
There are two main types of shockwave therapy used for plantar fasciitis: focused and radial. Focused shockwave therapy (f-ESWT) delivers concentrated energy to a precise point deep in the tissue. It typically requires anesthesia and is performed by a physician. Radial shockwave therapy spreads energy over a wider area, is less intense per pulse, and is usually done in an outpatient or clinic setting without sedation.
From an insurance perspective, this distinction rarely matters because most insurers deny both types. UnitedHealthcare’s policy explicitly names low energy, high energy, and radial wave therapy as unproven. The billing codes associated with shockwave for plantar fasciitis, including CPT 28890 (high-energy shockwave of the plantar fascia) and 0101T (musculoskeletal shockwave, not otherwise specified), are both subject to denial under these policies. The 0101T code is a Category III code, which insurers often treat as inherently investigational.
What You’ll Pay Out of Pocket
Without insurance coverage, shockwave therapy for plantar fasciitis typically costs $250 to $450 per session. Most treatment plans call for three to six sessions, putting the total cost between $750 and $2,700. Some clinics offer package pricing that brings the per-session cost down, and others offer payment plans.
Prices vary based on your geographic area, whether the provider uses focused or radial technology, and the clinical setting. A hospital-based orthopedic practice will generally charge more than a standalone sports medicine or podiatry clinic. It’s worth asking upfront whether the quoted price includes the ultrasound guidance that some focused shockwave protocols use.
How to Check Your Specific Plan
While the trend is toward denial, insurance coverage isn’t perfectly uniform. Regional Blue Cross Blue Shield plans, smaller insurers, and employer-sponsored plans with custom benefit designs occasionally handle ESWT differently. Some plans may cover it under certain conditions, particularly if you can document a long history of failed conservative treatment.
To find out where your plan stands, call the member services number on your insurance card and ask specifically about CPT code 28890 for plantar fasciitis. Have your provider submit a prior authorization request rather than simply billing after the fact. The prior authorization process forces the insurer to give you a coverage decision in writing before you commit to treatment.
If your claim is denied, insurers are required to explain the reason in writing. The most common basis is the “experimental/investigational” classification. You have the right to appeal, and appeals that include documentation of six or more months of failed conservative treatments (stretching, orthotics, physical therapy, injections) along with a letter of medical necessity from your provider have the strongest foundation. That said, overturning an experimental classification through appeal is difficult because it’s a policy-level exclusion rather than a case-by-case medical necessity decision.
Conservative Treatments Insurers Do Cover
Insurance plans consistently cover the standard conservative pathway for plantar fasciitis: physical therapy, custom or prefabricated orthotics (though custom orthotics may require prior authorization and documentation of failed first-line treatments), corticosteroid injections, night splints, and anti-inflammatory medications. Most guidelines recommend exhausting these options over at least six months before considering shockwave therapy anyway.
If conservative care fails and your insurer won’t cover shockwave therapy, the next covered option is usually surgical release of the plantar fascia. This is where the gap in coverage creates a frustrating situation: clinical guidelines recommend trying shockwave therapy before surgery, but many insurance plans will pay for the more invasive surgical option while refusing to cover the less invasive shockwave alternative.